{
    "ids": [
        [
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Effect of Termination-45",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Termination-44",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Expenses-46",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Severability-48",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Termination-17",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Termination Fee\u037e Certain Expenses-18",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Other Definitional and Interpretative Provisions-24",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Non-contravention-26",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Consents and Approvals-39",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Expenses Generally-19"
        ],
        [
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Solicitation of Proxies-2",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Taxes-29",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Litigation Related to the Merger-12",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-ANNEX B\u2014OPINION OF GOLDMAN SACHS & CO. LLC-22"
        ],
        [
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Entire Agreement-47",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Confidentiality-40",
            "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf-Intellectual Property Rights-28"
        ]
    ],
    "distances": [
        [
            0.347275972366333,
            0.34875768423080444,
            0.3799499273300171,
            0.39737287163734436,
            0.39986157417297363,
            0.4143370985984802,
            0.4226073622703552,
            0.4236378073692322,
            0.42694100737571716,
            0.4283389151096344
        ],
        [
            0.480692058801651,
            0.48541006445884705,
            0.4937587082386017,
            0.5303077101707458
        ],
        [
            0.3576415479183197,
            0.3628506660461426,
            0.45929035544395447
        ]
    ],
    "metadatas": [
        [
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 182,
                "Keyword": "Termination",
                "Section Header": "Effect of Termination",
                "Start Page": 182
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 182,
                "Keyword": "Termination",
                "Section Header": "Termination",
                "Start Page": 180
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 185,
                "Keyword": "Termination",
                "Section Header": "Expenses",
                "Start Page": 183
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 187,
                "Keyword": "Termination",
                "Section Header": "Severability",
                "Start Page": 186
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 110,
                "Keyword": "Termination",
                "Section Header": "Termination",
                "Start Page": 108
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 111,
                "Keyword": "Termination",
                "Section Header": "Termination Fee\u037e Certain Expenses",
                "Start Page": 110
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 139,
                "Keyword": "Termination",
                "Section Header": "Other Definitional and Interpretative Provisions",
                "Start Page": 138
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 145,
                "Keyword": "Termination",
                "Section Header": "Non-contravention",
                "Start Page": 145
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 176,
                "Keyword": "Termination",
                "Section Header": "Consents and Approvals",
                "Start Page": 174
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 111,
                "Keyword": "Termination",
                "Section Header": "Expenses Generally",
                "Start Page": 111
            }
        ],
        [
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 39,
                "Keyword": "Indemnification",
                "Section Header": "Solicitation of Proxies",
                "Start Page": 39
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 154,
                "Keyword": "Indemnification",
                "Section Header": "Taxes",
                "Start Page": 153
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 86,
                "Keyword": "Indemnification",
                "Section Header": "Litigation Related to the Merger",
                "Start Page": 85
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 189,
                "Keyword": "Indemnification",
                "Section Header": "ANNEX B\u2014OPINION OF GOLDMAN SACHS & CO. LLC",
                "Start Page": 189
            }
        ],
        [
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 186,
                "Keyword": "Confidentiality",
                "Section Header": "Entire Agreement",
                "Start Page": 186
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 177,
                "Keyword": "Confidentiality",
                "Section Header": "Confidentiality",
                "Start Page": 177
            },
            {
                "Document": "ChemoCentryx, Inc._20220914_DEFM14A_20340331_4518092.Pdf",
                "End Page": 153,
                "Keyword": "Confidentiality",
                "Section Header": "Intellectual Property Rights",
                "Start Page": 151
            }
        ]
    ],
    "documents": [
        [
            "Section 10.02. Effect of Termination. If this Agreement is terminated pursuant to Section 10.01, this Agreement shall become void and of no effect\nwithout liability of any party (or any stockholder, director, officer, employee, agent, consultant or representative of such party) to any other party hereto\u037e\nprovided, that such termination shall not relieve any party for any and all liabilities and damages incurred or suffered by the other party as a result of the\nFraud or a Willful Breach of this Agreement by such first party\u037e provided, further, that the provisions of Section 8.07, this Section 10.02 and Article 11\n(including, for the avoidance of doubt, Section 11.04) shall survive any termination hereof pursuant to Section 10.01 and remain in full force and effect.\nNothing shall limit or prevent any party from exercising any rights or remedies it may have under Section 11.13 in lieu of terminating this Agreement\npursuant to Section 10.01.\nARTICLE 11\nMISCELLANEOUS",
            "Section 10.01. Termination. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time:\n(a) by mutual written agreement of the Company and Parent\u037e or\n(b) by either the Company or Parent, if:\n(i) the Effective Time shall not have occurred on or before May 3, 2023 (the \u201cEnd Date\u201d)\u037e provided that if on the End Date any of the\nconditions set forth in Section 9.01(c) or Section 9.01(a) (to the extent\nA-51Table of Contents\nrelating to the matters set forth in Section 9.01(c)) shall not have been satisfied but all other conditions set forth in Article 9 shall have been\nsatisfied or waived (other than those conditions that by their terms are to be satisfied at the Closing, but provided that such conditions shall then\nbe capable of being satisfied if the Closing were to take place on such date), then the End Date shall be automatically extended to August 3, 2023\nbe capable of being satisfied if the Closing were to take place on such date), then the End Date shall be automatically extended to August 3, 2023\nand such date shall become the End Date for purposes of this Agreement\u037e and provided, further, that the right to terminate this Agreement\npursuant to this Section 10.01(b)(i) shall not be available to any party whose material breach of any provision of this Agreement shall have been\nthe primary cause, or resulted in, the failure of the Merger to be consummated by such time\u037e or\n(ii) if a court of competent jurisdiction or other Governmental Authority shall have issued an order, decree or ruling, or shall have taken any\nother action, having the effect of permanently restraining, enjoining or otherwise prohibiting the consummation of the Merger, which order, decree,\nruling or other action shall be final and nonappealable or any Governmental Authority that must grant an approval specified in Section 9.01(c) has\ndenied such approval, and such denial has become final and nonappealable\u037e provided that the right to terminate this Agreement pursuant to this\nSection 10.01(b)(ii) shall not be available to any party whose material breach of any provision of this Agreement shall have been the primary cause\nof, or resulted in, any of the events specified in this Section 10.01(b)(ii) occurring\u037e or\n(iii) the Company Stockholder Approval shall not have been obtained at the Company Stockholders\u2019 Meeting at which a vote on this\nAgreement is taken\u037e or\n(c) by Parent:\n(i) prior to obtaining the Company Stockholder Approval, if an Adverse Recommendation Change shall have occurred\u037e or\n(ii) prior to obtaining the Company Stockholder Approval, if there shall have been an intentional and material breach of Section 6.03\u037e or\n(iii) if a breach or failure to be true of any representation or warranty of the Company set forth in Article 4 or breach or failure to perform any\ncovenant or agreement set forth in this Agreement on the part of the Company shall have occurred such that the conditions set forth in Section\n9.02(a) or Section 9.02(b) would not be satisfied and cannot be cured by the Company prior to the End Date or, if capable of being cured, shall not\nhave been cured, following receipt by the Company from Parent of written notice of such breach or failure, by the earlier to occur of (x) thirty (30)\ndays after receipt of such notice from Parent and (y) the date that is two (2) days prior to the End Date\u037e provided that Parent shall not have the right\nto terminate this Agreement pursuant to this Section 10.01(c)(iii) if either Parent or Merger Subsidiary is then in material breach of any\nrepresentation, warranty, covenant or obligation under this Agreement\u037e or\n(d) by the Company:\n(i) prior to obtaining the Company Stockholder Approval, if (A) the Board of Directors has determined that an Acquisition Proposal\nconstitutes a Superior Proposal, (B) the Company has complied with its obligations set forth in Section 6.03(b)(ii), (C) the Company, substantially\nconcurrently with and as a condition to such termination, pays the Termination Fee payable pursuant to Section 11.04 and (D) substantially\nconcurrently with such termination, the Company enters into a definitive agreement in respect of a Superior Proposal in accordance with Section\n6.03\u037e or\n(ii) if a breach or failure to be true of any representation or warranty of Parent or Merger Subsidiary set forth in Article 5 or breach or failure to\nperform any covenant or agreement set forth in this Agreement on the part of Parent or Merger Subsidiary shall have occurred such that the\nconditions set forth in Section 9.03(a) or Section 9.03(b) would not be satisfied and cannot be cured by Parent prior to the End Date or, if capable of\nbeing cured, shall not have been cured, following receipt by Parent from the Company of written notice of such breach or failure, by the earlier to\noccur of (x) thirty (30) days after receipt of such\nA-52\nTable of Contents\nnotice from the Company and (y) the date that is two (2) days prior to the End Date\u037e provided that the Company shall not have the right to\nterminate this Agreement pursuant to this Section 10.01(d)(ii) if the Company is then in material breach of any representation, warranty, covenant or\nobligation under this Agreement.\nThe party desiring to terminate this Agreement pursuant to this Section 10.01 (other than pursuant to Section 10.01(a)) shall give notice of\ntermination to the other party specifying the reasons for such termination.\nSection 10.02.",
            "Section 11.04. Expenses.\n(a) General. Except as otherwise provided herein, all costs and expenses incurred in connection with this Agreement and the transactions\ncontemplated by this Agreement shall be paid by the party incurring such cost or expense.\n(b) Termination Fee.\n(i) If this Agreement is validly terminated by Parent pursuant to Section 10.01(c)(i) or Section 10.01(c)(ii) or by the Company pursuant to\nSection 10.01(d)(i), then the Company shall pay or cause to be paid to Parent in immediately available cash funds $119,314,679 (the \u201cTermination\nFee\u201d), in the case of a termination by Parent, within two (2) Business Days after such termination and, in the case of a termination by the Company,\nimmediately before and as a condition to such termination.\nA-54Table of Contents\n(ii) If (A) this Agreement is terminated (x) by Parent or the Company pursuant to Section 10.01(b)(i) (but in the case of termination by the\nCompany, only if at such time Parent would not be prohibited from terminating this Agreement pursuant to the proviso of Section 10.01(b)(i)) or (y)\nby Parent pursuant to Section 10.01(c)(iii), (B) after the date of this Agreement and prior to such termination, a bona fide Acquisition Proposal shall\nhave been publicly announced or otherwise been communicated to the Board of Directors and such Acquisition Proposal shall not have been\npublicly withdrawn prior to the time of the termination of this Agreement, and (C) prior to the date that is twelve (12) months following the date of\nsuch termination, the Company enters into a definitive agreement with respect to an Acquisition Proposal or an Acquisition Proposal shall have\nbeen consummated (in either case, whether or not the same Acquisition Proposal referred to in clause (B))\u037e provided that, for purposes of clause\n(C), each reference to \u201c20%\u201d in the definition of Acquisition Proposal shall be deemed to be a reference to \u201c50%\u201d, then the Company shall pay to\nParent the Termination Fee in immediately available funds, within two (2) Business Days after the consummation of the Acquisition Proposal\nreferred to in clause (C).\n(iii) If (A) this Agreement is terminated by Parent or the Company pursuant to Section 10.01(b)(iii), (B) after the date of this Agreement and\nprior to such termination, a bona fide Acquisition Proposal shall have been publicly announced and such Acquisition Proposal shall not have been\npublicly withdrawn at least two (2) Business Days prior to the Company Stockholders\u2019 Meeting, and (C) prior to the date that is twelve (12) months\nfollowing the date of such termination, the Company enters into a definitive agreement\nwith respect to an Acquisition Proposal or an Acquisition Proposal shall have been consummated (in either case, whether or not the same\nAcquisition Proposal referred to in clause (B))\u037e provided that, for purposes of clause (C), each reference to \u201c20%\u201d in the definition of Acquisition\nProposal shall be deemed to be a reference to \u201c50%\u201d, then the Company shall pay to Parent the Termination Fee in immediately available funds,\nwithin two (2) Business Days after the consummation of the Acquisition Proposal referred to in clause (C).\n(iv) In the event that this Agreement is validly terminated under circumstances where the Termination Fee is due and payable and Parent or\nits designee shall have received full payment of the Termination Fee pursuant to this Section 11.04(b) and any other amounts due pursuant to the\nsecond sentence of Section 11.04(c), the receipt of the Termination Fee and such other amounts shall be deemed to be liquidated damages for any\nand all losses or damages suffered or incurred by Parent, Merger Subsidiary, any of their respective Affiliates and Representatives or any other\nPerson in connection with this Agreement (and the termination hereof), the transactions contemplated by this Agreement (and the abandonment\nthereof) or any matter forming the basis for such termination, and none of Parent, Merger Subsidiary or any of their respective former, current or\nfuture officers, directors, partners, stockholders, optionholders, managers, members, Affiliates or Representatives (collectively, \u201cParent Related\nParties\u201d) or any other Person shall be entitled to bring or maintain any claim, action or proceeding against the Company Related Parties arising out\nof, relating to, or in connection with, this Agreement, any of the transactions contemplated by this Agreement or any matters forming the basis for\nsuch termination\u037e provided, however, that nothing in this Section 11.04(b)(iv) or Section 11.04(b)(v) below shall limit the rights of Parent under\nSection 11.13 or in the case of Fraud or Willful Breach.\n(v) Subject to the proviso in Section 11.04(b)(iv), Parent\u2019s right to receive payment from the Company of the Termination Fee pursuant to this\nSection 11.04(b) and any other amounts due pursuant to the second sentence of Section 11.04(c) shall be the sole and exclusive remedy of the\nParent Related Parties against the Company and any of its former, current or future officers, directors, partners, stockholders, optionholders,\nmanagers, members, Affiliates or Representatives (collectively, \u201cCompany Related Parties\u201d) in any circumstance in which the Termination Fee\nbecomes due and payable, and upon payment of the Termination Fee and such other amounts, none of the Company Related Parties shall have any\nfurther liability or obligation relating to, arising out of, or in connection with, this Agreement or the transactions contemplated by this Agreement.\nFor the avoidance of doubt, Parent may seek specific performance to cause the Company to consummate the Merger in accordance with Section\n11.13 or the payment of the Termination Fee pursuant to this Section 11.04(b), but in no event shall Parent be entitled to both (A) equitable relief\nA-55\nTable of Contents\nordering the Company to consummate the Merger in accordance with Section 11.13 and (B) the payment of the Termination Fee pursuant to this\nSection 11.04(b). Notwithstanding anything to the contrary contained herein, in no event shall the Company be required to pay the Termination Fee\non more than one occasion.\n(c) Other Costs and Expenses. The Company acknowledges that the agreements contained in this Section 11.04 are an integral part of the\ntransactions contemplated by this Agreement and that, without these agreements, Parent and Merger Subsidiary would not enter into this Agreement.\nAccordingly, if the Company fails promptly to pay any amount due to Parent pursuant to this Section 11.04, (i) the Company shall also pay any costs and\nexpenses incurred by Parent or Merger Subsidiary in connection with a legal action to enforce this Agreement that results in a judgment against the\nCompany for such amount payable pursuant to this Section 11.04 and (ii) the Company shall pay to Parent interest on such overdue amount (for the\nperiod commencing as of the date that such overdue amount was originally required to be paid pursuant to this Section 11.04 and ending on the date that\nsuch overdue amount is actually paid in full) at a rate per annum equal to the prime rate published in The Wall Street Journal on the date such payment\nwas required to be made plus five percent (5%), or such lesser rate per annum that is the maximum permitted under Applicable Law. Except as otherwise\nset forth in Section 2.03(c), all transfer, documentary, stamp, registration, and other similar Taxes imposed with respect to the Merger shall be borne by the\nCompany.\nSection 11.05.",
            "Section 11.12. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other\nGovernmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall\nremain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions\ncontemplated hereby is not affected in any manner materially adverse to any party. Upon such a\nA-57Table of Contents\ndetermination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in\nan acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.",
            "Termination\nThe Merger Agreement may be terminated and the transactions contemplated thereby, including the Merger, may be abandoned, at any time prior\nto the Effective Time, whether before or after the ChemoCentryx Stockholder Approval has been obtained (except as otherwise stated below), as follows:\n\u2022\nby mutual written agreement of ChemoCentryx and Amgen\u037e or\n\u2022\nby either ChemoCentryx or Amgen, if:\n\u2022\nthe Effective Time has not occurred on or before May 3, 2023 (referred to as the \u201cEnd Date\u201d)\u037e provided that if, as of such date, any of\nthe conditions to the closing with respect to (i) the expiration or termination of the waiting period applicable to the consummation of\nthe Merger under the HSR Act or (ii) the absence of any temporary restraining order, preliminary or permanent injunction, other order,\napplicable law or order issued by any governmental authority that directly or indirectly prevents, prohibits or makes illegal the\nconsummation of the Merger (to the extent relating to the HSR Act) is not satisfied but all other conditions to the closing of the\nMerger set forth in the Merger Agreement have been satisfied or waived (other than those conditions that by their terms are to be\nsatisfied at the closing, but provided that such conditions are then be capable of being satisfied if the closing were to take place on\nsuch date), then the End Date will be automatically extended to August 3, 2023 and such date will become the End Date for purposes\nof the Merger Agreement\u037e and provided, further, that this right to terminate the Merger Agreement will not be available to any party\nwhose material breach of any provision of the Merger Agreement has been the primary cause, or resulted in, the failure of the Merger\nto be consummated by such time\u037e or\n\u2022\na court of competent jurisdiction or other governmental authority has issued an order, decree or ruling, or has taken any other action,\nhaving the effect of permanently restraining, enjoining or otherwise prohibiting the consummation of the Merger, which order, decree,\nruling or other action is final and nonappealable or any governmental authority that must grant an approval specified in the\nconditions to closing relating to the expiration or termination of any applicable waiting period under the HSR Act has denied such\napproval, and such denial has become final and\n99Table of Contents\nnonappealable\u037e provided that this right to terminate the Merger Agreement will not be available to any party whose material breach of\nany provision of the Merger Agreement has been the primary cause of, or resulted in, any of the foregoing events\u037e or\n\u2022\nthe ChemoCentryx Stockholder Approval is not obtained at the Special Meeting at which a vote on the Merger Proposal is taken\u037e or\n\u2022\nby Amgen, if:\n\u2022\nprior to obtaining the ChemoCentryx Stockholder Approval, an Adverse Recommendation Change has occurred\u037e or\n\u2022\nprior to obtaining the ChemoCentryx Stockholder Approval, ChemoCentryx has intentionally and materially breached the non-\nsolicitation covenants applicable to ChemoCentryx pursuant to the Merger Agreement\u037e or\n\u2022\na breach or failure to be true of any representation or warranty of ChemoCentryx set forth in the Merger Agreement or a breach or\nfailure to perform any covenant or agreement set forth in the Merger Agreement on the part of ChemoCentryx shall have occurred\nwhich breach or failure would cause the conditions to Amgen\u2019s and Merger Sub\u2019s obligations to consummate the Merger relating to\nthe accuracy of ChemoCentryx\u2019s representations and warranties or the performance of ChemoCentryx\u2019s agreements and covenants to\nnot be satisfied and such breach or failure cannot be cured by ChemoCentryx prior to the End Date or, if capable of being cured, is not\ncured, following receipt by ChemoCentryx from Amgen of written notice of such breach or failure, by the earlier to occur of (x) thirty\n(30) days after receipt of such notice from Amgen and (y) the date that is two (2) days prior to the End Date\u037e provided that Amgen will\nnot have this right to terminate the Merger Agreement if either Amgen or Merger Sub is then in material breach of any representation,\nwarranty, covenant or obligation of Amgen or Merger Sub under the Merger Agreement\u037e or\n\u2022\nby ChemoCentryx, if:\n\u2022\nprior to obtaining the ChemoCentryx Stockholder Approval, (A) the Board has determined that an Acquisition Proposal constitutes a\nSuperior Proposal, (B) ChemoCentryx has complied with certain of its covenants and agreements set forth in the Merger Agreement\nwith respect to, among other matters, non-solicitation of Acquisition Proposals and providing notice to Amgen of such Acquisition\nProposal and ChemoCentryx\u2019s intent to terminate the Merger Agreement and, if requested by Amgen, discussing and negotiating\nwith Amgen any proposed amendments or modifications to the terms of the Merger Agreement, and as more fully described under\n\u201cThe Merger Agreement\u2014No Solicitation\u037e ChemoCentryx Acquisition Proposals\u037e Adverse Recommendation Change\u201d beginning on\npage 89 of this proxy statement, (C) ChemoCentryx, substantially concurrently with and as a condition to such termination, pays the\nTermination Fee payable to Amgen pursuant to the Merger Agreement as more fully described under \u201cThe Merger Agreement\u2014",
            "Termination Fee\u037e Certain Expenses\nChemoCentryx must pay to Amgen a termination fee of $119,314,679 (referred to as the \u201cTermination Fee\u201d) in cash in the event that the Merger\nAgreement is validly terminated:\n\u2022\nby Amgen because, prior to obtaining the ChemoCentryx Stockholder Approval, (i) an Adverse Recommendation Change has occurred or\n(ii) there has been an intentional and material breach of the non-solicitation covenants applicable to ChemoCentryx under the Merger\nAgreement\u037e\n\u2022\nby ChemoCentryx prior to obtaining ChemoCentryx Stockholder Approval to accept a Superior Proposal and, substantially concurrently\nwith such termination, enter into a definitive agreement with respect to such Superior Proposal\u037e\n\u2022\n(i) by either ChemoCentryx or Amgen because the Merger has not been consummated by the End Date (subject, in the case of such a\ntermination by ChemoCentryx, to certain conditions set forth in the Merger Agreement) or (ii) by Amgen because ChemoCentryx breached\nor failed to perform any representation, warranty, covenant or agreement set forth in the Merger Agreement and fails to timely cure such\nbreach or failure, if curable, and in each case:\n\u2022\nafter August 3, 2022, and prior to such termination, a bona fide Acquisition Proposal has been publicly announced or otherwise\ncommunicated to the Board and such Acquisition Proposal has not been publicly withdrawn prior to the time of the termination of the\nMerger Agreement\u037e and\n\u2022\nprior to the date that is twelve (12) months following the date of such termination, ChemoCentryx enters into a definitive agreement\nwith respect to an Acquisition Proposal or an Acquisition Proposal is consummated (in either case, whether or not the same\nAcquisition Proposal referred to above)\u037e provided that, for purposes of this provision, each reference to \u201c20%\u201d in the definition of\nAcquisition Proposal is a reference to \u201c50%\u201d)\u037e and provided further that the Termination Fee payable pursuant to this provision will\nbe payable by ChemoCentryx only upon consummation of an Acquisition Proposal\u037e\n\u2022\nby either ChemoCentryx or Amgen because the ChemoCentryx Stockholder Approval is not obtained at the Special Meeting at which a vote\non the Merger Proposal is taken and:\n\u2022\nafter August 3, 2022, and prior to such termination, a bona fide Acquisition Proposal is publicly announced and such Acquisition\nProposal is not publicly withdrawn at least two (2) business days prior to the Special Meeting, and\n\u2022\nprior to the date that is twelve (12) months following the date of such termination, ChemoCentryx enters into a definitive agreement\nwith respect to an Acquisition Proposal or an Acquisition Proposal is consummated (in either case, whether or not the same\nAcquisition Proposal referred to above)\u037e provided that, for purposes of this provision, each reference to \u201c20%\u201d in the definition of\nAcquisition Proposal is a reference to \u201c50%\u201d)\u037e and provided further that the Termination Fee payable pursuant to this provision will\nbe payable by ChemoCentryx only upon consummation of an Acquisition Proposal.\nOther than in the case of fraud or willful breach, if the Merger Agreement is validly terminated in circumstances in which the Termination Fee is due\nand payable, Amgen\u2019s receipt of the Termination Fee (and applicable costs, expenses and interest as set forth in the Merger Agreement and described\nbelow) will be deemed to be liquidated damages for any and all losses or damages suffered or incurred by Amgen, Merger Sub, any of their respective\naffiliates and representatives or any other person in connection with the Merger\n101Table of Contents\nAgreement (or its termination) or the transactions contemplated by the Merger Agreement, and none of Amgen, Merger Sub, or any of their respective\nformer, current or future officers, directors, partners, stockholders, optionholders, managers, members, affiliates or representatives (referred to,\ncollectively, as the \u201cAmgen Related Parties\u201d) or any other person will be entitled to bring or maintain any claim, action or proceeding against\nChemoCentryx and any of its former, current or future officers, directors, partners, stockholders, optionholders, managers, members, affiliates or\nrepresentatives (referred to, collectively, as the \u201cChemoCentryx Related Parties\u201d) arising out of, relating to, or in connection with, the Merger Agreement\n(or its termination) or the transactions contemplated by the Merger Agreement.\nThe Merger Agreement further provides that, other than in the case of fraud or willful breach, Amgen\u2019s right to receive payment from\nChemoCentryx of the Termination Fee (and applicable costs, expenses and interest as set forth in the Merger Agreement and described below) is the sole\nand exclusive remedy of the Amgen Related Parties against the ChemoCentryx Related Parties in circumstances in which the Termination Fee becomes\ndue and payable, and that upon payment of the Termination Fee (and any such applicable costs, expenses and interest), none of the ChemoCentryx\nRelated Parties will have any further liability or obligation relating to, arising out of, or in connection with, the Merger Agreement or the transactions\ncontemplated by the Merger Agreement.\nChemoCentryx is not obligated to pay the Termination Fee on more than one occasion.",
            "Section 1.02. Other Definitional and Interpretative Provisions. The words \u201chereof,\u201d \u201cherein\u201d and \u201chereunder\u201d and words of like import used in this\nAgreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for\nconvenience of reference only and shall be ignored in the construction or interpretation hereof. References to Articles, Sections, Exhibits and Schedules\nare to Articles, Sections, Exhibits and Schedules of this Agreement unless otherwise specified. All Exhibits and Schedules annexed hereto or referred to\nherein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Exhibit or Schedule or\nin any certificate or other document made or delivered pursuant hereto but not otherwise defined therein, shall have the meaning as defined in this\nAgreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the context may\nrequire, any pronoun shall include the corresponding masculine, feminine and neuter forms. The word \u201cwill\u201d shall be construed to have the same meaning\nas the word \u201cshall.\u201d The word \u201cor\u201d shall not be exclusive. The word \u201cextent\u201d or phrase \u201cto the extent\u201d means the degree to which something extends, and\ndoes not mean merely \u201cif\u201d. Whenever the words \u201cinclude,\u201d \u201cincludes\u201d or \u201cincluding\u201d are used in this Agreement, they shall be deemed to be followed by\nthe words \u201cwithout limitation,\u201d whether or not they are in fact followed by those words or words of like import. \u201cWriting,\u201d \u201cwritten\u201d and comparable terms\nrefer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to \u201cordinary course\u201d or \u201cordinary\ncourse of business\u201d or words of similar import with respect to any Person shall mean action taken, or omitted to be taken, by such Person in the ordinary\ncourse of such Person\u2019s business. References to any statute shall be deemed to refer to such statute as amended from time to time and to any rules or\nregulations promulgated thereunder. References to any agreement or contract are to that agreement or contract as amended, modified or supplemented\nfrom time to time in accordance with the terms hereof and thereof (provided, that any such references in the Company Disclosure Schedule shall only\nrefer to such amendments, modifications or supplements made available by or on behalf of the Company to\nA-9Table of Contents\nParent prior to the date hereof). References to any Person include the successors and permitted assigns of that Person. References from or through any\ndate mean, unless otherwise specified, from and including or through and including, respectively. References to \u201cmade available\u201d with respect to any\ndocument or other information mean such document or other information was (i) provided by one party or its representatives to the other party and its\nrepresentatives, (ii) uploaded by a party or its representatives to the virtual data room of such party and made fully available and visible to the other party\nand its representatives in such virtual data room or (iii) filed by a party with the SEC and publicly available on EDGAR, in each case at least twenty-four\n(24) hours prior to the time of determination. References to \u201claw,\u201d \u201claws\u201d or to a particular statute or law shall be deemed also to include any Applicable\nLaw. References to the date hereof mean to the date of this Agreement.\nARTICLE 2\nTHE MERGER\nSection 2.01.",
            "Section 4.04. Non-contravention. The execution, delivery and performance by the Company of this Agreement and the consummation of the\ntransactions contemplated hereby do not and will not (a) contravene, conflict with, or result in any violation or breach of any provision of the Company\nCertificate or bylaws of the Company or the articles of incorporation or bylaws (or equivalent organizational documents) of any Subsidiary of the\nCompany, (b) assuming compliance with the matters referred to in Section 4.03, contravene, conflict with or result in a violation or breach of any provision\nof any Applicable Law, (c) require any consent or other action by any Person under, constitute a default under, or cause or permit the termination,\ncancellation, acceleration or other change of any right or obligation or the loss of any benefit to which the Company or any of its Subsidiaries is entitled\nunder any provision of any Material Contract or (d) result in the creation or imposition of any Lien on any property or asset of the Company or any of its\nSubsidiaries, with only such exceptions, in the case of each of clauses (b) through (d), as would not reasonably be expected to have, individually or in the\naggregate, a Material Adverse Effect on the Company.",
            "Section 8.01. Consents and Approvals.\n(a) Subject to the terms and conditions of this Agreement, each of the parties shall use its reasonable best efforts to take, or cause to be taken, all\nactions, to file, or cause to be filed, all documents and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things\nnecessary, proper or advisable under Antitrust Laws or other Applicable Law to consummate and make effective the transactions contemplated by this\nAgreement as soon as reasonably practicable, including using reasonable best efforts to (i) obtain all necessary actions or nonactions, waivers,\nconsents, clearances, decisions, declarations, approvals and, expirations or terminations of waiting periods from Governmental Authorities and make all\nnecessary registrations and filings and take all steps as may be reasonably necessary to obtain any such consent, decision, declaration, approval,\nclearance or waiver, or expiration or termination of a waiting period by or from, or to avoid an action or proceeding by, any Governmental Authority in\nconnection with any Antitrust Law\u037e (ii) obtain all other approvals, consents, ratifications, permissions, waivers or authorizations from Governmental\nAuthorities or other Third Parties necessary, proper or advisable in connection with the transactions contemplated by this Agreement\u037e and (iii) execute\nand deliver any additional instruments necessary to consummate the transactions contemplated by this Agreement\u037e provided, that, in connection with\nany of the foregoing clauses (i) through (iii), the Company shall not agree to (x) make any payment of a consent fee, \u201cprofit sharing\u201d payment or other\nconsideration (including increased or accelerated payment) or concede anything of monetary or economic value or (y) amend, supplement or modify any\ncontract in any manner that would be adverse to the interest of the Company or, after the Merger, Parent and its Subsidiaries, in each case, without the\nprior written consent of Parent.\n(b) The parties agree to use their reasonable best efforts to promptly take, and cause their Affiliates to take, all actions and steps requested or\nrequired by any Governmental Authority as a condition to granting any consent, permit, authorization, waiver, clearance or approval, and to cause the\nprompt expiration or termination of any\nA-45Table of Contents\napplicable waiting period and to resolve objections, if any, of the U.S. Federal Trade Commission (the \u201cFTC\u201d) or U.S. Department of Justice (\u201cDOJ\u201d), or\nother Governmental Authorities of any other jurisdiction for which consents, permits, authorizations, waivers, clearances, approvals and expirations or\nterminations of waiting periods are required with respect to the transactions contemplated hereby, so as to obtain such consents, permits, authorizations,\nwaivers, clearances, approvals or termination of the waiting period under the HSR Act or other Antitrust Laws, and to avoid the commencement of a\nlawsuit by the FTC, the DOJ or other Governmental Authorities under Antitrust Laws, and to avoid the entry of, or to effect the dissolution of, any order\nin any action or legal proceeding which would otherwise have the effect of preventing the Closing or delaying the Closing beyond the End Date. Such\nreasonable best efforts by the parties and/or their Affiliates shall include (1) proffering and consenting and/or agreeing to the sale, divestiture, licensing\nor other disposition, or the holding separate, of particular assets, categories of assets or portions of any business of the Company or any of its\nSubsidiaries, (2) promptly effecting the disposition, licensing or holding separate of particular assets, categories of assets or portions of any business of\nthe Company or any of its Subsidiaries and (3) agreeing to such limitations on the conduct or actions with respect to any particular assets, categories of\nassets or portions of any business of the Company or any of its Subsidiaries, in each case, as may be required in order to enable the consummation of the\ntransactions contemplated hereby to occur as soon as reasonably practicable (and in any event no later than the End Date) (the actions referred to in\nclauses (1), (2) and (3), \u201cRemedy Actions\u201d)\u037e provided, however, that (i) neither Parent nor any of its Affiliates shall be required to proffer, consent to or\nagree to or effect any Remedy Action with respect to (A) any assets, categories of assets or portions of any business of Parent or any of its Subsidiaries\n(other than solely the Company and its Subsidiaries, subject to the following clause (B)) or (B) any assets, categories of assets or portions of any\nbusiness of the Company or any of its Subsidiaries if, in the case of this clause (B), any such Remedy Action would, individually or in the aggregate,\nreasonably be expected to be material to the business, assets or financial condition of the Company and its Subsidiaries, taken as a whole\u037e and provided,\nthat the Company shall only be permitted to proffer, consent to or agree to or effect any Remedy Action with the prior written consent of Parent\u037e\nprovided, further, that in no event shall Parent, the Company or their respective Subsidiaries be required to proffer, consent to or agree to or effect any\nRemedy Action unless such Remedy Action is conditioned upon the consummation of the Merger.\n(c) Subject to the terms and conditions of this Agreement, each of the parties shall (and shall cause their respective Affiliates, if applicable, to)\npromptly, but in no event later than ten (10) Business Days after the date hereof unless otherwise agreed to in writing by Parent and the Company, make\nan appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the transactions contemplated by this Agreement.\n(d) Without limiting the generality of anything contained in this Section 8.01, from the date of hereof until the Effective Time or the termination or\nthis Agreement in accordance with its terms, each of the Company and Parent (on its and Merger Subsidiary\u2019s behalf) shall use its reasonable best efforts\nto (i) cooperate in all respects and consult with each other in connection with any filing or submission in connection with any investigation or other\ninquiry, including allowing the other party to have a reasonable opportunity to review in advance and comment on drafts of filings and submissions, (ii)\ngive the other party prompt notice of the making or commencement of any request, inquiry, investigation, action or legal proceeding brought by a\nGovernmental Authority or brought by a Third Party before any Governmental Authority, in each case, with respect to the transactions contemplated by\nthis Agreement, (iii) keep the other party promptly informed as to the status of any such request, inquiry, investigation, action or legal proceeding, (iv)\npromptly inform the other party of any communication to or from the FTC, DOJ or any other Governmental Authority in connection with any such\nrequest, inquiry, investigation, action or legal proceeding, (v) promptly furnish to the other party, subject to an appropriate confidentiality agreement to\nlimit disclosure to outside counsel and consultants retained by such counsel, with copies of documents provided to or received from any Governmental\nAuthority in connection with any such request, inquiry, investigation, action or legal proceeding, (vi) subject to an appropriate confidentiality agreement\nto limit disclosure to counsel and outside consultants retained by such counsel, consult in advance and cooperate with the other party and consider in\ngood faith the views of the other party in connection with any substantive communication, analysis, appearance, presentation, memorandum, brief,\nargument, opinion or\nA-46\nTable of Contents\nproposal to be made or submitted in connection with any such request, inquiry, investigation, action or legal proceeding, and (vii) except as may be\nprohibited by any Governmental Authority or by Applicable Law, in connection with any such request, inquiry, investigation, action or legal proceeding\nin respect of the transactions contemplated by this Agreement, each party shall provide advance notice of and permit authorized Representatives of the\nother party to be present at each meeting or conference, including any virtual or telephonic meetings, relating to such request, inquiry, investigation,\naction or legal proceeding and to have access to and be consulted in advance in connection with any argument, opinion or proposal to be made or\nsubmitted to any Governmental Authority in connection with such request, inquiry, investigation, action or legal proceeding\u037e provided, however, that\nmaterials required to provided pursuant to this Section 8.01(d) may be redacted (A) to remove references concerning the valuation of Parent, Merger\nSubsidiary, the Company, or any of their respective Subsidiaries or assets, (B) as necessary to comply with contractual arrangements, and (C) as\nnecessary to address reasonable privilege concerns. Each party shall supply as promptly as practicable such information, documentation, other material\nor testimony that may be reasonably requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with\nany reasonable request for additional information, documents or other materials received by any party or any of their respective Subsidiaries from any\nGovernmental Authority in connection with such applications or filings for the transactions contemplated by this Agreement. Parent shall pay all filing\nfees under the HSR Act and other Antitrust Laws, but the Company shall bear its own costs for the preparation of any such filings.\nSection 8.02.",
            "Expenses Generally\nExcept as otherwise described above or provided in the Merger Agreement, whether or not the Merger is consummated, ChemoCentryx and Amgen\nare each responsible for all of their respective costs and expenses incurred in connection with the Merger and the transactions contemplated by the\nMerger Agreement.\nThe Merger Agreement provides that, if ChemoCentryx fails to pay Amgen the Termination Fee when due and payable, (i) ChemoCentryx will also\npay any costs and expenses incurred by Amgen or Merger Sub in connection with a legal action to enforce the Merger Agreement that results in a\njudgment against ChemoCentryx for payment of the Termination Fee and (ii) ChemoCentryx will also pay to Amgen interest on such overdue amount (for\nthe period commencing as of the date that such overdue amount was originally required to be paid and ending on the date that such overdue amount is\nactually paid in full) at a rate per annum equal to the prime rate published in The Wall Street Journal on the date such payment was required to be made\nplus five percent (5%), or such lesser rate per annum that is the maximum permitted under applicable law."
        ],
        [
            "Solicitation of Proxies\nThe Board is soliciting your proxy, and we will bear the cost of the solicitation of proxies.\nWe have retained MacKenzie Partners, Inc., a proxy solicitation firm, to solicit proxies in connection with the Special Meeting at a cost of\napproximately $25,000 plus expenses. We will also indemnify the proxy solicitor against losses arising out of its provisions of these services on our\nbehalf. In addition, we may reimburse banks, brokers and other nominees representing beneficial owners of shares for their expenses in forwarding\nsoliciting materials to such beneficial owners. Proxies may also be solicited by our directors, officers and employees, personally or by telephone, email,\nfax, over the Internet or other means of communication. No additional compensation will be paid for such services.",
            "Section 4.17. Taxes. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse\nEffect on the Company:\n(a) All Tax Returns required by Applicable Law to be filed with any Governmental Authority by or on behalf of the Company or any of its\nSubsidiaries have been filed when due (taking into account applicable extensions) in accordance with all Applicable Laws, and all such Tax Returns are\ntrue and complete in all respects.\n(b) The Company and each of its Subsidiaries has timely paid (or has had timely paid on its behalf) to the appropriate Governmental Authority all\nTaxes due and payable (whether or not shown on any Tax Return). All Taxes that the Company or any of its Subsidiaries is or was required by Applicable\nLaw to withhold or collect have been duly and timely withheld or collected, and have been duly and timely paid (or set aside for payment when due) to\nthe appropriate Governmental Authority.\n(c) The unpaid Taxes of the Company and each of its Subsidiaries did not, as of the Company Balance Sheet Date, exceed the reserve or accrual for\nTax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the\nCompany Balance Sheet (rather than in any notes thereto) in accordance with GAAP. None of the Company or any of its Subsidiaries has incurred any\nliability for Taxes since the Company Balance Sheet Date other than in the ordinary course of business or in connection with the Merger.\n(d) There is no written claim, audit, action, suit, proceeding, examination or investigation pending or threatened in writing against or with respect to\nthe Company or its Subsidiaries in respect of any Taxes or Tax matters.\n(e) During the two-year period ending on the date hereof, neither the Company nor any of its Subsidiaries was a distributing corporation or a\ncontrolled corporation in a transaction intended to be governed by Section 355 of the Code (or any similar provision of state, local or foreign law).\n(f) There are no Liens for Taxes on any of the assets of the Company or any of its Subsidiaries other than Permitted Liens.\n(g) No jurisdiction in which the Company or a Subsidiary of the Company does not file Tax Returns has made a claim in writing which has not been\nresolved that the Company or such Subsidiary is or may be liable for\nA-24Table of Contents\nTax in that jurisdiction. None of the Company or any of its Subsidiaries has been subject to Tax in any jurisdiction other than its country of incorporation\nby virtue of having a permanent establishment (as defined by applicable Tax treaty) or other place of business or taxable presence in that jurisdiction.\n(h) There are no currently effective waivers of any statute of limitations with respect to Taxes or extensions of time with respect to a Tax assessment\nor deficiency\n(i) No adjustment with respect to any Tax Return, claim for any additional Tax, or deficiency for Taxes has been received by the Company or any of\nits Subsidiaries, except for such adjustment, claim, or deficiency that has been fully satisfied by payment, settled or withdrawn. All assessments for Taxes\ndue with respect to completed and settled examinations or any concluded litigation have been fully paid.\n(j) Neither the Company nor any of its Subsidiaries (i) is or has been a member of any affiliated, consolidated, combined, unitary or similar group for\npurposes of filing Tax Returns or paying Taxes (other than a group the common parent of which is the Company or any of its Subsidiaries), (ii) is a party\nto or bound by, or has any obligation under, any agreement or arrangement relating to the apportionment, sharing, assignment, allocation or\nindemnification of or for any Tax or Tax asset (other than (A) an agreement solely between or among the Company and any of its Subsidiaries or (B) an\nagreement entered into in the ordinary course of business that does not have as a principal purpose addressing Tax matters) or (iii) has any liability for\nTaxes of any Person (other than the Company or any of its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any analogous or similar\nprovision of state, local or foreign Tax law), as transferee or successor, by contract or otherwise. None of the Company or its Subsidiaries has made an\nelection under Section 965(h) of the Code.\n(k) None of the Company or any of its Subsidiaries has been a party to any \u201clisted transaction\u201d within the meaning of Treasury Regulations Section\n1.6011-4(b)(2).\nSection 4.18.",
            "Litigation Related to the Merger\nOn September 2, 2022, a purported stockholder of ChemoCentryx filed a lawsuit in the United States District Court for the Northern District of\nCalifornia captioned Meinking v. ChemoCentryx, Inc., Case No. 3:22-cv-05019-LB. The complaint names ChemoCentryx and members of the Board as\ndefendants and alleges that the defendants made materially incomplete and misleading statements about the proposed acquisition of ChemoCentryx by\nAmgen. Specifically, the complaint alleges that all defendants violated Section 14(a) of the Exchange Act and that each Board member violated Section\n20(a) of the Exchange Act, and asserts claims challenging the adequacy of disclosures regarding ChemoCentryx\u2019s projections, Goldman\u2019s financial\nanalyses, and the sales process leading up to the proposed transaction in the preliminary proxy statement filed with the SEC on August 31, 2022 (the\n\u201cPreliminary Proxy\u201d). The complaint seeks, among other relief, (i) injunctive relief preventing the parties from proceeding with the Merger until the alleged\ndisclosure deficiencies have been remedied, (ii) rescission in the event the Merger is consummated or alternatively rescissory damages and (iii) an award\nof costs, including attorneys\u2019 and experts\u2019 fees. ChemoCentryx believes this lawsuit is without merit.\n76Table of Contents\nAdditional lawsuits may be filed against ChemoCentryx, members of the Board or ChemoCentryx\u2019s officers in connection with the Merger, which\ncould prevent or delay completion of the Merger and result in substantial costs to ChemoCentryx, including any costs associated with indemnification.",
            "Annex B\nOpinion of Goldman Sachs & Co. LLC\n200 West Street | New York, NY 10282-2198\nTel: 212-902-1000 | Fax: 212-902-3000\nPERSONAL AND CONFIDENTIAL\nAugust 3, 2022\nBoard of Directors\nChemoCentryx, Inc.\n835 Industrial Road, Suite 600\nSan Carlos, CA 94070\nLadies and Gentlemen:\nYou have requested our opinion as to the fairness from a financial point of view to the holders (other than Amgen Inc. (\u201cBuyer\u201d) and its affiliates)\nof the outstanding shares of common stock, par value $0.001 per share (the \u201cShares\u201d), of ChemoCentryx, Inc. (the \u201cCompany\u201d) of the $52.00 in cash per\nShare to be paid to such holders pursuant to the Agreement and Plan of Merger, dated as of August 3, 2022 (the \u201cAgreement\u201d), by and among Buyer,\nCarnation Merger Sub, Inc., a wholly owned subsidiary of Buyer, and the Company.\nGoldman Sachs & Co. LLC and its affiliates are engaged in advisory, underwriting and financing, principal investing, sales and trading, research,\ninvestment management and other financial and non-financial activities and services for various persons and entities. Goldman Sachs & Co. LLC and its\naffiliates and employees, and funds or other entities they manage or in which they invest or have other economic interests or with which they co-invest,\nmay at any time purchase, sell, hold or vote long or short positions and investments in securities, derivatives, loans, commodities, currencies, credit\ndefault swaps and other financial instruments of the Company, Buyer, any of their respective affiliates and third parties, or any currency or commodity\nthat may be involved in the transaction contemplated by the Agreement (the \u201cTransaction\u201d). We have acted as financial advisor to the Company in\nconnection with, and have participated in certain of the negotiations leading to, the Transaction. We expect to receive fees for our services in connection\nwith the Transaction, the principal portion of which is contingent upon consummation of the Transaction, and the Company has agreed to reimburse\ncertain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement. We have provided certain financial\nadvisory and/or underwriting services to Buyer and/or its affiliates from time to time for which our Investment Banking Division has received, and may\nreceive, compensation, including having acted as financial advisor to Buyer in connection with its acquisition of Five Prime Therapeutics in April 2021\u037e as\nbookrunner in connection with the public offering by Buyer of its 1.650% Senior Notes due 2028 (aggregate principal amount $1,250,000,000), 2.000%\nSenior Notes due 2032 (aggregate principal amount $1,250,000,000), 2.800% Senior Notes due 2041 (aggregate principal amount $1,150,000,000), 3.000%\nSenior Notes due 2052 (aggregate principal amount $1,350,000,000) in August 2021\u037e as financial advisor to Buyer in connection with its acquisition of\nTeneobio, Inc. in October 2021\u037e and as bookrunner in connection with the public offering by Buyer of its 3.000% Senior Notes due 2029 (aggregate\nprincipal amount $750,000,000), 3.350% Senior Notes due 2032 (aggregate principal amount $1,000,000,000), 4.200% Senior Notes due 2052 (aggregate\nprincipal amount $1,000,000,000), 4.400% Senior Notes due 2062 (aggregate principal amount $1,250,000,000) in February 2022. We may also in the future\nprovide financial advisory and/or underwriting services to the Company, Buyer and their respective affiliates for which our Investment Banking Division\nmay receive compensation.\nB-1"
        ],
        [
            "Section 11.11. Entire Agreement. This Agreement, the Confidentiality Agreement and the Additional Confidentiality Agreement constitute the entire\nagreement between the parties with respect to the subject matter herein and therein and supersede all prior agreements and understandings, both oral and\nwritten, between the parties with respect to the subject matter herein and therein.",
            "Section 8.07. Confidentiality. The parties acknowledge that Parent and the Company have previously executed the Confidentiality Agreement and\nthat certain Confidentiality Agreement dated as of February 17, 2022 (the \u201cAdditional Confidentiality Agreement\u201d), which Confidentiality Agreement and\nAdditional Confidentiality Agreement will continue in full force and effect in accordance with their respective terms.\nSection 8.08.",
            "Section 4.16. Intellectual Property Rights.\n(a) Section 4.16(a) of the Company Disclosure Schedule identifies (i) the name of the applicant/registrant, (ii) the date and jurisdiction of\napplication/registration (including with respect to domain names, the applicable Internet domain name registrar), (iii) the application or registration\nnumber and (iv) any other co-owners, in each case, for each item of material Registered IP owned in whole or in part by the Company or any of its\nSubsidiaries or exclusively licensed to the Company or any of its Subsidiaries. Each of the patents and patent applications included in such material\nRegistered IP properly identifies by name each and every inventor of the claims thereof as determined in accordance with Applicable Law, and proper\ninvention assignments for such inventors have been timely filed with the United States Patent and Trademark Office or its foreign equivalent, to the\nextent necessary or advisable under Applicable Law. The material Registered IP is subsisting, and, to the knowledge of the Company, the issued and\ngranted items included therein are valid and enforceable. No interference, opposition, reissue, reexamination or other proceeding of any nature (other than\nordinary course initial examination proceedings at the United States Patent and Trademark Office and foreign equivalents thereof) is pending or, to the\nknowledge of the Company, threatened, in which the scope, validity, enforceability, inventorship or ownership of any Registered IP is being or has been\ncontested or challenged.\nA-22Table of Contents\n(b) The Company owns and possesses all right, title and interest in and to all material Company IP owned or purported to be owned by the\nCompany or any of its Subsidiaries (\u201cOwned Company IP\u201d) (except for the right, title and interest of any co-owner disclosed on Section 4.16(a) of the\nCompany Disclosure Schedule), free and clear of all Liens (other than Permitted Liens). To the knowledge of the Company, the Company and its\nSubsidiaries own or have the right to use all material Intellectual Property Rights used in or necessary for (i) the business of the Company and its\nSubsidiaries as currently conducted and as proposed to be conducted, and (ii) the development, manufacturing and commercialization (in each case, as\ncurrently conducted and as proposed to be conducted) of the products or product candidates, including the Product, that are in clinical development or\nbeing marketed or sold by or on behalf of the Company or its Subsidiaries, which, in each case will be owned or available for use, following the\nconsummation of the transactions contemplated by this Agreement, on the same terms (including the same payment obligations) as they were owned or\navailable for use by the Company and its Subsidiaries immediately prior to the Effective Time. No employee, director, independent contractor or\nconsultant of the Company or any of its Subsidiaries or other Person (other than as disclosed on Section 4.16(a) of the Company Disclosure Schedule)\nowns or has any claim, right (whether or not currently exercisable) or interest to or in any Owned Company IP and each employee, director, independent\ncontractor or consultant of the Company or any of its Subsidiaries who is or was involved in the creation or development of any Intellectual Property\nRights on behalf of the Company or any of its Subsidiaries, pursuant to such individual\u2019s activities on behalf of the Company or any of its Subsidiaries,\nhas signed a written agreement containing a present assignment to the Company or its applicable Subsidiary of Intellectual Property Rights arising from\nsuch activities and appropriate confidentiality provisions protecting the Owned Company IP.\n(c) No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution\nhas been or is being used to create Owned Company IP or, to the knowledge of the Company, any other material Company IP, except for any such funding\nor use of facilities or personnel that has not and would not reasonably be expected to result in such Governmental Authority or institution obtaining any\nownership rights to (or the right to obtain any ownership rights to) such Company IP, or any rights to receive royalties or other rights to use or exploit\nany Company IP.\n(d) Section 4.16(d) of the Company Disclosure Schedule sets forth each license agreement pursuant to which the Company or any of its\nSubsidiaries (i) has a license or other right to any material Intellectual Property Right that is used to develop, manufacture or commercialize, or is\nincorporated into or distributed with, any product or product candidate of the Company or any of its Subsidiaries, including the Product (other than any\nmaterial transfer agreements, services agreements, clinical trial agreements, non-disclosure agreements, commercially available Software-as-a-Service\nofferings, or commercially available off-the-shelf software licenses, in each case, entered into in the ordinary course of business) (each an \u201cInbound\nLicense\u201d) or (ii) has granted a license or other right to any material Company IP (other than any material transfer agreements, services agreements, clinical\ntrial agreements, non-disclosure agreements, or non-exclusive outbound licenses, in each case, entered into in the ordinary course of business) (each an\n\u201cOutbound License\u201d).\n(e) (i) To the knowledge of the Company, neither the operation of the business of the Company or its Subsidiaries nor the making, use, import, sale,\noffer for sale or other disposition of any product or product candidate of the Company or any of its Subsidiaries, including the Product, infringes,\nmisappropriates or otherwise violates or has infringed, misappropriated or otherwise violated since January 1, 2020 any Intellectual Property Right of any\nother Person\u037e and (ii) to the knowledge of the Company, no other Person is infringing, misappropriating or otherwise violating or has infringed,\nmisappropriated or otherwise violated any Company IP since January 1, 2020. No action, suit, investigation or proceeding is pending or has been served\nsince January 1, 2020 (or, to the knowledge of the Company, is being threatened) against the Company or any of its Subsidiaries or by the Company or\nany of its Subsidiaries relating to any actual, alleged or suspected infringement, misappropriation or other violation of any Intellectual Property Rights of\nanother Person or of the Company IP. Since January 1, 2020, none of the Company or any of its Subsidiaries has received or asserted any written notice\nA-23\nTable of Contents\nor other written communication (including cease and desist letters) relating to any actual, alleged or suspected infringement, misappropriation or other\nviolation of any Intellectual Property Right of another Person by the Company or any of its Subsidiaries or of any Company IP by any other Person.\n(f) The Company and its Subsidiaries have taken reasonable security and other measures to protect the Company IP, including reasonable measures\nagainst unauthorized disclosure, to maintain and protect the secrecy, confidentiality and value of its trade secrets and other technical information, and to\nthe knowledge of the Company, such trade secrets and other technical information have not been used by, disclosed to or uncovered by any Person\nexcept pursuant to written, valid and appropriate non-disclosure agreements which have not been breached.\n(g) None of the Company or any of its Subsidiaries has been a member or promoter of, or a contributor to any industry standards body or any\nsimilar organization that would require or obligate the Company or any of its Subsidiaries to grant or offer to any other Person any license or right to any\nCompany IP.\n(h) None of the Company IP is subject to any pending or outstanding order, judgment, decree, injunction or other disposition of dispute that\nadversely and materially restricts the use, transfer, registration or licensing of any such Company IP by the Company or any of its Subsidiaries.\nSection 4.17."
        ]
    ]
}